Cell and Gene Outsourcing

  1. Bispecific T- Cell Engager (BiTE) Screening, Automated Pipeline 5/1/2026

    View automated, high‑throughput BiTE screening in mammalian cells, enabling rapid discovery of efficacious variants through precise genomic integration and scalable workflows.

  2. Start Fast, Scale Seamlessly: Why A Different Oncology Model Was Needed 5/1/2026

    Oncology programs don’t lose momentum because the science fails, but because execution fractures as complexity grows. Learn how continuity-first operating models help sponsors move faster.

  3. Delivering Oncology Clinical Trial Excellence Worldwide 5/1/2026

    Accelerate oncology programs with deep therapeutic expertise and global scale. Master the complexities of ADCs and cell therapies through agile execution and high-retention project teams.

  4. Advancing Formulation Strategies for Complex Drug Products 4/30/2026

    An event-focused overview examining how formulation development and stability strategies support robust, scalable drug products discussed at the DDF Summit Berlin.

  5. Engineering Precision In Genetic Medicines 4/30/2026

    Precision genome editing strategies that balance specificity and potency through advanced engineering workflows, AI‑driven optimization, and tailored editor design for clinical genetic medicines.

  6. Cell And Gene Therapy CDMOs: On The Path To $75 Billion in Services? 4/30/2026

    Cell and gene therapy (CGT) developers – and thus their service providers – have had their share of ups and downs. But what do the promise and uneven realities of these therapies add up to in the development and manufacturing outsourcing sector? According to a Towards Healthcare report, despite the bumps in the road, in 2025 the global CGT CDMO market grew to $8.2 billion. What of future predictions? Here's a detailed analysis.

  7. The European CDMO Model, Powering Biologics Innovation 4/29/2026

    Europe’s integrated CDMO model is reshaping biologics development by aligning early science, manufacturing, and quality to accelerate scalable, compliant therapies from concept to clinic.

  8. LENTIVERSE™ VectorCraft: Smarter Lentiviral Vector Design 4/29/2026

    VectorCraft is a custom lentiviral vector design and manufacturing offering for programs where complex biology is driving development and early decisions have long-term consequences.

  9. LENTIVERSE™ LaunchSuite: Point‑Of‑Care CAR‑T Manufacturing 4/29/2026

    LaunchSuite is a ready‑to‑deploy point‑of‑care CAR‑T manufacturing solution for established targets, combining GMP vector supply, streamlined cell processing, and fit‑for‑purpose workflows.

  10. Simtra Capabilities Update April 2026: Fill/Finish 4/28/2026

    A look at sterile injectable expansion highlighting investment, advanced fill‑finish technologies, and flexible manufacturing from development to commercial production.